The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality care for patients with tenosynovial giant cell tumor: A multidisciplinary quality improvement initiative.
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; Ayala Pharmaceuticals; Bayer; C4 Therapeutics; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; Foghorn Therapeutics; Kowa Pharmaceutical; Lilly; Medpacto; Mundipharma; Servier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Seth Pollack
Consulting or Advisory Role - Apexigen; Bayer; Daichii Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Obsidian Therapeutics; Sensei Biotherapeutics; T-Knife
Speakers' Bureau - Deciphera
Research Funding - Obsidian Therapeutics (Inst)
 
Jeffrey D. Carter
No Relationships to Disclose
 
Cherilyn Heggen
No Relationships to Disclose
 
Kelly E. McKinnon
No Relationships to Disclose